Marc Beer has almost twenty-five years of experience in commercialization and development in pharmaceutical services, diagnostics, devices, and biotechnology. In 2016, he co-founded Renovia together with Yolanda Lorie and Ramon Iglesias. They closed series A financing successfully with leading healthcare capital venture funds. In 2000 Beer became the Chief executive Officer of ViaCell. ViaCell is a biotechnology company that specializes in the development, collection and preservation of umbilical cord stem cells. In a period of seven years, Marc led ViaCell through a series of rapid growth and robust commercial organization. The company went public in 2005 and was acquired by PerkinElmer in 2007. At the time he was serving at ViaCell as CEO. He was also serving in the board of directors of Erytech Pharma as a member. This is a biopharmaceutical company that is publicly traded.
Before joining ViaCell, Marc Beer was the vice president of Genzyme. As the head of global marketing, he was responsible for launching commercial products that address rare diseases affecting a global population. Before joining Genzyme, he worked at Abbot Laboratories under the pharmaceutical and diagnostic division in various roles. He was also a member of Mass Life Science Board of Commonwealth of Massachusetts. He served on the Governing Board of the Biotechnology Industry Organization Emerging Companies Section. Marc was the founding Chairman of the compensation committee and chairman of the board of directors of Good Start Genetics. The company was acquired by InVitae recently. He is also a member of the Minerva neurosciences audit committee. Marc Beer serves on the Business Advisory Council of Miami University.
Rinovia has decided to move forward with new products that treat pelvic floor disorders. On Tuesday the company made a Series B round worth $32 million and a venture debt of $10 million. The company is now developing several therapeutic and diagnostic products for treating pelvic floor disorder. One of this disorder is urinary incontinence which is estimated to affect 250 million women in the whole world. In April, Leva, Renova’s first products received FDA approval. The Longwood Fund recently joined the Series B round. The investing firm had earlier invested in Renovia. The funds will assist in testing and developing four diagnostic and therapeutic products. This includes a new generation of Leva device.
Marc Beer recently said that Renovia is thrilled to have a group of healthcare investors who share in the vision of the company supporting it. The vision of the company is to treat, diagnose and improve lives of many women affected by pelvic floor disorders. Customers will be able to get valuable data with the proprietary and innovative sensor technologies. This will drive great understanding and knowledge of pelvic disorders, inform new treatment options and lower healthcare costs in the long term. Learn more: https://www.businesswire.com/news/home/20180821005199/en/Renovia-Completes-42.3-Million-Series-Financing